TW202200133A - 達立克生(daridorexant)之醫藥用途 - Google Patents
達立克生(daridorexant)之醫藥用途 Download PDFInfo
- Publication number
- TW202200133A TW202200133A TW110113975A TW110113975A TW202200133A TW 202200133 A TW202200133 A TW 202200133A TW 110113975 A TW110113975 A TW 110113975A TW 110113975 A TW110113975 A TW 110113975A TW 202200133 A TW202200133 A TW 202200133A
- Authority
- TW
- Taiwan
- Prior art keywords
- sleep
- daytime
- darixan
- insomnia
- individual
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| WOPCT/EP2020/060940 | 2020-04-19 | ||
| EP2020060940 | 2020-04-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202200133A true TW202200133A (zh) | 2022-01-01 |
Family
ID=75478068
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110113975A TW202200133A (zh) | 2020-04-19 | 2021-04-19 | 達立克生(daridorexant)之醫藥用途 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230134935A1 (https=) |
| EP (1) | EP4138822A1 (https=) |
| JP (1) | JP7822954B2 (https=) |
| KR (1) | KR20230004670A (https=) |
| CN (1) | CN115427037A (https=) |
| AU (1) | AU2021260018A1 (https=) |
| BR (1) | BR112022020924A2 (https=) |
| CA (1) | CA3175369A1 (https=) |
| CL (1) | CL2022002855A1 (https=) |
| IL (1) | IL297234A (https=) |
| MX (1) | MX2022011179A (https=) |
| PH (1) | PH12022552763A1 (https=) |
| TW (1) | TW202200133A (https=) |
| WO (1) | WO2021213923A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115925699B (zh) * | 2022-02-25 | 2023-10-03 | 南京知和医药科技有限公司 | 具有镇痛活性的稠环化合物及其制备方法与用途 |
| WO2024019978A2 (en) * | 2022-07-19 | 2024-01-25 | Rutgers, The State University Of New Jersey | Therapeutic combinations and methods |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013502447A (ja) * | 2009-08-24 | 2013-01-24 | グラクソ グループ リミテッド | 睡眠障害の治療のためのオレキシン受容体アンタゴニストとしての５−メチル−ピペリジン誘導体 |
| ES2617863T3 (es) | 2012-06-04 | 2017-06-20 | Actelion Pharmaceuticals Ltd. | Derivados de bencimidazol-prolina |
| MY179862A (en) | 2013-12-03 | 2020-11-18 | Idorsia Pharmaceuticals Ltd | Crystalline form of (s)-(2-(6-chloro-7-methyl-1h-benzo[d]imidazol-2-yl)-2-methylpyrrolidin-1 -yl)(5-methoxy-2-(2h-1,2,3-triazol-2-yl)phenyl)methanone and its use as orexin receptor antagonists |
| UA119151C2 (uk) | 2013-12-03 | 2019-05-10 | Ідорсія Фармасьютікалз Лтд | КРИСТАЛІЧНА СОЛЬОВА ФОРМА (S)-(2-(6-ХЛОР-7-МЕТИЛ-1H-БЕНЗО[d]ІМІДАЗОЛ-2-ІЛ)-2-МЕТИЛПІРОЛІДИН-1-ІЛ)(5-МЕТОКСИ-2-(2H-1,2,3-ТРИАЗОЛ-2-ІЛ)ФЕНІЛ)МЕТАНОНУ ЯК АНТАГОНІСТ ОРЕКСИНОВОГО РЕЦЕПТОРА |
| SI3077391T1 (sl) | 2013-12-04 | 2018-11-30 | Idorsia Pharmaceuticals Ltd | Uporaba benzimidazol-prolinskih derivatov |
| ES2843952T3 (es) | 2014-10-23 | 2021-07-21 | Eisai R&D Man Co Ltd | Composiciones para tratar el insomnio |
| LT3619199T (lt) | 2017-05-03 | 2021-09-27 | Idorsia Pharmaceuticals Ltd | 2-([1,2,3]triazol-2-il)-benzenkarboksirūgšties darinių gamyba |
-
2021
- 2021-04-16 EP EP21718142.9A patent/EP4138822A1/en active Pending
- 2021-04-16 WO PCT/EP2021/059943 patent/WO2021213923A1/en not_active Ceased
- 2021-04-16 IL IL297234A patent/IL297234A/en unknown
- 2021-04-16 PH PH1/2022/552763A patent/PH12022552763A1/en unknown
- 2021-04-16 BR BR112022020924A patent/BR112022020924A2/pt not_active Application Discontinuation
- 2021-04-16 KR KR1020227040124A patent/KR20230004670A/ko active Pending
- 2021-04-16 AU AU2021260018A patent/AU2021260018A1/en active Pending
- 2021-04-16 US US17/996,499 patent/US20230134935A1/en active Pending
- 2021-04-16 CN CN202180028992.7A patent/CN115427037A/zh active Pending
- 2021-04-16 JP JP2022563036A patent/JP7822954B2/ja active Active
- 2021-04-16 CA CA3175369A patent/CA3175369A1/en active Pending
- 2021-04-16 MX MX2022011179A patent/MX2022011179A/es unknown
- 2021-04-19 TW TW110113975A patent/TW202200133A/zh unknown
-
2022
- 2022-10-17 CL CL2022002855A patent/CL2022002855A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA3175369A1 (en) | 2021-10-28 |
| JP2023521492A (ja) | 2023-05-24 |
| BR112022020924A2 (pt) | 2023-02-14 |
| AU2021260018A1 (en) | 2022-12-22 |
| MX2022011179A (es) | 2022-10-07 |
| WO2021213923A1 (en) | 2021-10-28 |
| KR20230004670A (ko) | 2023-01-06 |
| JP7822954B2 (ja) | 2026-03-03 |
| IL297234A (en) | 2022-12-01 |
| US20230134935A1 (en) | 2023-05-04 |
| EP4138822A1 (en) | 2023-03-01 |
| CL2022002855A1 (es) | 2023-06-02 |
| CN115427037A (zh) | 2022-12-02 |
| PH12022552763A1 (en) | 2024-03-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2281771C2 (ru) | Использование декстрометорфана и ингибитора оксидазы для отучения пациентов от наркотиков и антидепрессантов | |
| US20060122127A1 (en) | Methods for reducing the side effects associated with mirtzapine treatment | |
| US20060252761A1 (en) | Augmentation of extinction via administration of sub-antimicrobial doses of D-cycloserine | |
| TW200403997A (en) | Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders | |
| US12485100B2 (en) | Treatment of menstrual cycle-induced symptoms | |
| JP7822954B2 (ja) | ダリドレキサントの医学的用途 | |
| Ciraulo et al. | Sedative hypnotics | |
| AU2010303903B2 (en) | Method of treating cravings by administration of nerve growth factor | |
| EA051128B1 (ru) | Медицинское применение даридорексанта | |
| Brown et al. | Psychiatric disorders | |
| Collins et al. | Pediatric cancer pain | |
| Morin et al. | Insomnia in adults | |
| Kalko et al. | Potential risks and pharmacological safety features of hypnotics. Music therapy as a non-drug way to improve sleep quality | |
| Kalko et al. | Potential risk and pharmacological safety features of hypnotics. Music therapy as a non-drug way to improve sleep quality | |
| HK40112834A (zh) | 用於痴呆和神经变性病况中的激越、精神病和认知衰退的环苯扎林治疗 | |
| HK40075517B (en) | Treatment of menstrual cycle-induced symptoms | |
| HK40075517A (en) | Treatment of menstrual cycle-induced symptoms | |
| Fleming | 3.3 Sleep Difficulties and Disorders in Older Adults, and Their Management | |
| Henderson | Managing insomnia in the primary care setting | |
| REINEMER | APPROVED BY THE GRADUATE COUNCIL, COLLEGE^ PF—DENTISTRY:(signed) _ f Assistant Dean of Research and Advanced Education APPROVED BY THE GRADUATE COUNCIL | |
| BRALEY et al. | Sleeptions among persons with comorbidmultiple sclero-condi | |
| Neubauer et al. | Pharmacological Management of Insomnia | |
| Lippmann et al. | Problems with sleep: What should the doctor do? | |
| Battrum-Mounts | A comparison of two conventional sedatives-diazepam and droperidol in combination with fentanyl in surgical patients |